Delayed
Canadian Securities Exchange
12:26:33 16/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.1
CAD
|
-9.09%
|
|
+11.11%
|
+17.65%
|
Fiscal Period: July |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
14.26
|
66.89
|
24.73
|
38.18
|
11.37
|
11.88
|
Enterprise Value (EV)
1 |
16.11
|
57.88
|
26.01
|
38.7
|
23.04
|
30.26
|
P/E ratio
|
-6.53
x
|
-12.7
x
|
-5.44
x
|
-16.8
x
|
-0.39
x
|
-0.52
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.91
x
|
14.5
x
|
4.68
x
|
1.49
x
|
0.36
x
|
0.52
x
|
EV / Revenue
|
6.68
x
|
12.5
x
|
4.92
x
|
1.51
x
|
0.73
x
|
1.33
x
|
EV / EBITDA
|
-14.9
x
|
-23.6
x
|
-5.18
x
|
15.3
x
|
-17.9
x
|
-5.16
x
|
EV / FCF
|
-10.1
x
|
-27.6
x
|
-8.48
x
|
10.2
x
|
16.7
x
|
-15.2
x
|
FCF Yield
|
-9.91%
|
-3.62%
|
-11.8%
|
9.84%
|
6%
|
-6.57%
|
Price to Book
|
1.32
x
|
2.02
x
|
0.74
x
|
1.11
x
|
1.18
x
|
-1.16
x
|
Nbr of stocks (in thousands)
|
47,775
|
97,273
|
1,07,514
|
1,09,078
|
1,13,669
|
1,46,637
|
Reference price
2 |
0.2985
|
0.6876
|
0.2300
|
0.3500
|
0.1000
|
0.0810
|
Announcement Date
|
13/11/18
|
13/11/19
|
15/12/20
|
18/11/21
|
17/01/23
|
14/11/23
|
Fiscal Period: July |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2.413
|
4.612
|
5.287
|
25.7
|
31.64
|
22.82
|
EBITDA
1 |
-1.081
|
-2.455
|
-5.025
|
2.537
|
-1.284
|
-5.868
|
EBIT
1 |
-1.151
|
-2.744
|
-5.481
|
0.6487
|
-3.52
|
-7.67
|
Operating Margin
|
-47.69%
|
-59.5%
|
-103.66%
|
2.52%
|
-11.12%
|
-33.61%
|
Earnings before Tax (EBT)
1 |
-2.686
|
-3.753
|
-4.464
|
0.1902
|
-25.63
|
-18.15
|
Net income
1 |
-1.781
|
-3.753
|
-4.341
|
-2.261
|
-28.68
|
-20.78
|
Net margin
|
-73.81%
|
-81.37%
|
-82.09%
|
-8.8%
|
-90.64%
|
-91.07%
|
EPS
2 |
-0.0457
|
-0.0540
|
-0.0423
|
-0.0208
|
-0.2556
|
-0.1547
|
Free Cash Flow
1 |
-1.596
|
-2.097
|
-3.066
|
3.81
|
1.383
|
-1.99
|
FCF margin
|
-66.14%
|
-45.46%
|
-57.99%
|
14.82%
|
4.37%
|
-8.72%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
150.17%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/11/18
|
13/11/19
|
15/12/20
|
18/11/21
|
17/01/23
|
14/11/23
|
Fiscal Period: July |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1.85
|
-
|
1.28
|
0.53
|
11.7
|
18.4
|
Net Cash position
1 |
-
|
9
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-1.712
x
|
-
|
-0.2554
x
|
0.2075
x
|
-9.093
x
|
-3.133
x
|
Free Cash Flow
1 |
-1.6
|
-2.1
|
-3.07
|
3.81
|
1.38
|
-1.99
|
ROE (net income / shareholders' equity)
|
-32.1%
|
-17.1%
|
-13.8%
|
-5.84%
|
-127%
|
-5,308%
|
ROA (Net income/ Total Assets)
|
-8.98%
|
-6.63%
|
-9.13%
|
0.93%
|
-5.56%
|
-18.4%
|
Assets
1 |
19.84
|
56.61
|
47.54
|
-242.4
|
515.9
|
113.2
|
Book Value Per Share
2 |
0.2300
|
0.3400
|
0.3100
|
0.3100
|
0.0800
|
-0.0700
|
Cash Flow per Share
2 |
0.0100
|
0.0900
|
0.0100
|
0.0700
|
0.0200
|
0.0100
|
Capex
1 |
0.56
|
0.37
|
0.87
|
0.4
|
0.83
|
0.99
|
Capex / Sales
|
23.39%
|
7.98%
|
16.49%
|
1.57%
|
2.62%
|
4.35%
|
Announcement Date
|
13/11/18
|
13/11/19
|
15/12/20
|
18/11/21
|
17/01/23
|
14/11/23
|
|
1st Jan change
|
Capi.
|
---|
| +45.15% | 6.34B | | -14.00% | 4.61B | | +9.54% | 3.39B | | -8.99% | 3.29B | | +50.03% | 2.02B | | -6.97% | 1.73B | | -0.31% | 1.67B | | +50.00% | 1.63B | | -10.61% | 1.59B |
Alternative Medicine
|